This congress will be delivered as a hybrid (on-site or virtual) experience due to COVID-19 pandemic spread.
This congress will provide clinicians with cutting-edge updates on recent advances in the treatment of breast cancer, from preclinical breakthroughs to changes in clinical treatment paradigms. Novel agents and improved regimens, coupled with more in-depth molecular and phenotypic subtyping, are driving the future of breast cancer therapy. This dynamic program will focus on the practical implications of emerging data for patient care in the clinic. Recent data and their clinical impact are highlighted throughout the program, with expert perspectives on how to apply the evidence to individualize therapy for patients with breast cancer. Current areas of controversy or uncertainty will also be debated, with discussion of ongoing clinical trials and investigational approaches designed to address these questions. This congress provides an opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with international leaders in the field of breast cancer in order to increase knowledge, apply new data to practice, and, ultimately, improve patient outcomes.
Hot Topics for 2021:
- Integration and sequencing of new therapeutic options for HER2-positive breast cancer, including the management of patients with brain metastases
- New data concerning immunotherapy, PARP inhibition, antibody-drug conjugates, and other novel approaches for triple-negative breast cancer
- The latest developments in targeted therapy for hormone receptor–positive breast cancer, including CDK4/6 inhibitors and PI3K/Akt inhibitors
- Utilization of biomarkers and gene expression assays to personalize therapy
15.25 AMA PRA Category 1 Credits™; 15.25 ABIM MOC points; 15.25 CNE contact hours
Venue: Sheraton San Diego Hotel & Marina
July 30-31, 2021
San Diego, California 92101, United States